Purchase price allocation | |
US$’000 | |
Consideration: | |
Cash paid to shareholders | |
621 | |
Shares issued to shareholders | |
372 | |
Deferred consideration | |
244 | |
Total Consideration | |
1,237 |
Fair value of net assets acquired: | |
Cash and cash equivalents | |
12 | |
Trade and other receivables | |
12 | |
Trade and other payables | |
(2) | |
Borrowings | |
(42) | |
Intangible assets identified on acquisition: | |
Customer Relationship | |
150 | |
Regulatory asset | |
507 | |
Deferred tax liability on intangible assets | |
(164) | |
Total net assets | |
473 | |
Goodwill | |
764 | |
Total | |
1,237 |
Company | ||||
Country of | ||||
registration or | ||||
incorporation | Registered office | Principal activity | ||
Percentage of ordinary | ||||
shares held | ||||
HeiQ Materials AG | Switzerland | |||
Rütistrasse 12, 8952 | ||||
Schlieren Zurich | ||||
Development, | ||||
production and sale of | ||||
chemicals | ||||
100% | ||||
HeiQ ChemTex Inc. | United States | |||
2725 Armentrout Dr, | ||||
Concord, NC 28025 | ||||
Development, | ||||
production and sale of | ||||
chemicals | ||||
100% | ||||
HeiQ Pty Ltd | Australia | |||
Level 20/181 William Street, | ||||
Melbourne, VIC 3000 | ||||
Research and | ||||
development | ||||
100% | ||||
HeiQ GrapheneX AG | Switzerland | |||
Rütistrasse 12, 8952 | ||||
Schlieren Zurich | ||||
Research and | ||||
development | ||||
100% | ||||
HeiQ Company Limited | Taiwan | |||
No. 14 & 16, Ln. 50, Wufu | ||||
1st Rd. Luzhu District, | ||||
Taoyuan City 33850 | ||||
Distribution | 100% | |||
HX Company Limited | Taiwan | |||
No. 14 & 16, Ln. 50, Wufu | ||||
1st Rd. Luzhu District, | ||||
Taoyuan City 33850 | ||||
Trading and | ||||
production | ||||
66.7% | ||||
HeiQ Iberia Unipessoal | ||||
Lda | ||||
Portugal | ||||
Rua Engº Frederico Ulrich, nº | ||||
2650, 4470-605 Maia | ||||
Sales agency and | ||||
internal services | ||||
company | ||||
100% |
Company | ||||
Country of | ||||
registration or | ||||
incorporation | Registered office | Principal activity | ||
Percentage of ordinary | ||||
shares held | ||||
Chrisal NV | Belgium | |||
Priester Daensstraat 9, | ||||
3920 Lommel, Belgium | ||||
Biotechnology | 71% | |||
HeiQ RAS AG | Germany | |||
Rudolf Vogt Straße 8-10, | ||||
93053 Regensburg | ||||
Materials innovation | 100% | |||
HeiQ Regulatory GmbH | Germany | |||
Rudolf Vogt Straße 8-10, | ||||
93053 Regensburg | ||||
Materials innovation | 100% | |||
HeiQ (China) Material | ||||
Tech LTD | ||||
China | ||||
Room 2501, Xuhui | ||||
Commercial Mansion, No. | ||||
168 Yude Road, Shanghai | ||||
Distribution | 100% | |||
Life Material Technologies | ||||
Limited | ||||
Hong Kong | ||||
Alexandra House, 6th Floor, | ||||
16-20 Chater Road, Central | ||||
Materials technology | 100% | |||
Life Natural Limited | Hong Kong | |||
Alexandra House, 6th Floor, | ||||
16-20 Chater Road, Central | ||||
Inactive | 100% | |||
LMT Holding Limited | Thailand | |||
222 Lumpini Building 2, 247 | ||||
Rajdamri Road | ||||
Lumpini, Phatumwan, | ||||
Bangkok 10330 | ||||
Holding | 96.45% | |||
Life Material Technologies | ||||
Limited | ||||
Thailand | ||||
222 Lumpini Building 2, 247 | ||||
Rajdamri Road | ||||
Lumpini, Phatumwan, | ||||
Bangkok 10330 | ||||
Trading | 99.995% | |||
HeiQ AeoniQ GmbH | Austria | |||
Industriestrasse 35, 3130 | ||||
Herzogenburg | ||||
Materials Innovation | 96% | |||
Chem-Tex Laboratories | ||||
Inc. | ||||
United States | ||||
2725 Armentrout Dr, | ||||
Concord, NC 28025 | ||||
Chemical production | ||||
site | ||||
100% | ||||
Beijing HeiQ Material Tech | ||||
Co., Ltd. | ||||
China | ||||
Room 17B9870, Floor 17, | ||||
101 Nei, -4 to 33, Building | ||||
13, Wangjing Dongyuan | ||||
Siqu, Chaoyang District, | ||||
Beijing | ||||
Inactive/Distribution | 100% | |||
HeiQ AeoniQ Holding AG | Switzerland | Parkstrasse 1, 5234 Villigen | Holding | 95.95% |
Tarn-Pure Holdings Ltd | United Kingdom | |||
Castle Court, 6 Cathedral | ||||
Road, Cardiff, CF11 9LJ | ||||
Holding | 100% | |||
Tarn Pure (IP) Limited | ||||
United Kingdom | ||||
Castle Court, 6 Cathedral | ||||
Road, Cardiff, CF11 9LJ | ||||
Holder of intellectual | ||||
property | ||||
100% | ||||
Tarn-Pure AG Ltd. | ||||
United Kingdom | ||||
Castle Court, 6 Cathedral | ||||
Road, Cardiff, CF11 9LJ | ||||
Trading | 100% | |||
Tarn-Pure Ireland Limited | Ireland | |||
C/O Duggan & Power, Odeon | ||||
House 7, Eyre Square, Co. | ||||
Galway | ||||
Trading | 100% | |||
HeiQ AeoniQ Portugal | Portugal | |||
Rua Engº Frederico Ulrich, nº | ||||
2650, 4470-605 Maia | ||||
Materials Innovation | 100% |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Revenue by organizational unit | ||
US$’000 | US$’000 | |
Advanced Materials | ||
50,697 | 38,366 | |
LifeSciences | ||
6,988 | 6,164 | |
Other activities | ||
4,633 | 2,872 | |
Total revenue | ||
62,318 | 47,202 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Revenue by timing of revenue | ||
US$’000 | US$’000 | |
Goods transferred at a point in time | ||
56,860 | 45,002 | |
Services | ||
transferred at a point in time | ||
1,914 | 160 | |
Services transferred over time | ||
3,544 | 2,040 | |
Total revenue | ||
62,318 | 47,202 |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Unsatisfied performance obligations | ||
US$’000 | US$’000 | |
Exclusivity services | ||
1,200 | 2,100 | |
Research and development services | ||
5,087 | 3,750 | |
Total unsatisfied performance obligations | ||
6,287 | 5,850 |
Advanced Materials | LifeSciences | Other activities | ||||||
Total | ||||||||
US$’000 | ||||||||
Period | ||||||||
23/24 | ||||||||
Year | ||||||||
2022 | ||||||||
Period | ||||||||
23/24 | ||||||||
Year | ||||||||
2022 | ||||||||
Period | ||||||||
23/24 | ||||||||
Year | ||||||||
2022 | ||||||||
Period | ||||||||
23/24 | ||||||||
Year | ||||||||
2022 | ||||||||
Revenue | ||||||||
50,697 | 38,366 | 6,988 | 6,164 | 4,633 | 2,672 | 62,318 | 47,202 | |
Operating profits (loss) | ||||||||
(4,391) | (14,347) | (1,385) | (5,537) | (13,206) | (9,361) | (18,982) | (29,245) | |
Financial result | ||||||||
(1,441) | (590) | |||||||
Loss before taxation | ||||||||
(20,423) | (29,835) | |||||||
Taxation | ||||||||
(915) | 21 | |||||||
Loss after taxation | ||||||||
(21,338) | (29,814) | |||||||
Depreciation and amortization | ||||||||
Property, plant and equipment | ||||||||
1,200 | 362 | 453 | 335 | 662 | 585 | 2,315 | 1,282 | |
Right-of use assets | ||||||||
383 | 165 | 218 | 145 | 972 | 628 | 1,573 | 938 | |
Intangible Assets | ||||||||
1,512 | 773 | 837 | 550 | 889 | 112 | 3,238 | 1,435 | |
Impairment loss | ||||||||
Property, plant and equipment | ||||||||
- | - | - | 730 | - | - | - | 730 | |
Intangible Assets | ||||||||
323 | 8,247 | - | 2,402 | - | 1,002 | 323 | 11,651 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Revenue by region | ||
US$’000 | US$’000 | |
North & South America | ||
26,726 | 20,425 | |
Asia | ||
18,911 | 13,376 | |
Europe | ||
16,228 | 13,109 | |
Others | ||
453 | 293 | |
Total revenue | ||
62,318 | 47,202 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Non -current assets by region | ||
US$’000 | US$’000 | |
Europe | ||
30,379 | 22,290 | |
Asia | ||
2,226 | 8,102 | |
North & South America | ||
7,318 | 7,734 | |
Others | ||
176 | 612 | |
Total non-current assets | ||
40,099 | 38,738 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Cost of sales | ||
US$’000 | US$’000 | |
Material expenses | ||
30,086 | 20,942 | |
Personnel expenses | ||
4,682 | 2,830 | |
Depreciation of property, plant and equipment | ||
892 | 652 | |
Inventory allowance increase (reduction) | ||
(427) | 4,912 | |
Other costs of sales | ||
4,252 | 4,409 | |
Total cost of sales | ||
39,485 | 33,745 |
Period ended | Year ended | |
June 30, | December | |
31, | ||
2024 | 2022 | |
Other income | ||
US$’000 | US$’000 | |
Gain on disposal of property plant and equipment | ||
23 | 21 | |
Gain on earnout consideration payable (Note 5g) | ||
138 | - | |
Foreign exchange gains | ||
121 | 3,539 | |
Fair value gain on derivative liabilities (Note 38) | ||
367 | 371 | |
Income from out-of-court settlement | ||
2,750 | - | |
Other income | ||
1,243 | 901 | |
Total other income | ||
4,642 | 4,832 |
Period ended | Year ended | |
June 30, | December 31, | |
Selling and general administration expenses | ||
2024 | ||
US$’000 | ||
2022 | ||
US$’000 | ||
Personnel expenses | ||
19,324 | 14,977 | |
Depreciation of property, plant and equipment | ||
1,423 | 630 | |
Amortization of intangible assets | ||
3,238 | 1,435 | |
Depreciation of right-of | ||
-use assets | ||
1,573 | 938 | |
Net credit losses on financial assets and contract assets | ||
1,025 | 85 | |
Other | ||
17,186 | 12,904 | |
Total selling and general administration expense | ||
43,769 | 30,969 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Auditor’s remuneration | ||
US$’000 | US$’000 | |
Audit of Group performed by Group Auditor | ||
443 | 1,180* | |
Audit of subsidiaries performed by local auditors | 77 | 122 |
Total fees for audit services | ||
520 | 1,302 | |
Audit related assurance services | ||
- | - | |
Other assurance services | ||
- | - | |
Total auditor remuneration | ||
- | - |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Personnel expenses | ||
US$’000 | US$’000 | |
Wages & salaries | ||
21,273 | 15,274 | |
Social security & other payroll taxes | ||
2,249 | 1,685 | |
Pension costs | ||
306 | 710 | |
Share-based payments | ||
178 | 138 | |
Total personnel expenses | ||
24,006 | 17,807 | |
Reported as cost of sales (Note 9) | ||
4,682 | 2,830 | |
Reported as selling and general administration expense (Note 11) | ||
19,324 | 14,977 | |
Total personnel expenses | ||
24,006 | 17,807 | |
The average monthly number of employees was as follows: | ||
194 | ||
218 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Other expenses | ||
US$’000 | US$’000 | |
Foreign exchange losses | ||
343 | 3,050 | |
Loss on disposal of property, plant and equipment | ||
204 | 16 | |
Transaction costs relating to mergers and acquisitions | ||
23 | 50 | |
Write off intangible assets (Note 18) | ||
1,419 | 897 | |
Other | ||
376 | 171 | |
Total other expenses | ||
2,365 | 4,184 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Finance income | ||
US$’000 | US$’000 | |
Interest income | ||
18 | 5 | |
Gains on foreign currency transactions | ||
157 | 678 | |
Other | ||
27 | - | |
Total finance income | ||
202 | 683 |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Finance costs | ||
US$’000 | US$’000 | |
Amortization of deferred finance costs – acquisition costs | ||
3 | - | |
Lease finance expense | ||
311 | 163 | |
Interest on borrowings | ||
586 | 110 | |
Bank fees | ||
364 | 98 | |
Loss on foreign currency transactions | ||
379 | 902 | |
Total finance costs | ||
1,643 | 1,273 |
Period ended | ||||
June 30, 2024 | ||||
Year ended | ||||
December 31, 2022 | ||||
US$’000 | Tax rate % | US$’000 | Tax rate % | |
Expected tax at average | ||||
tax rate | ||||
(3,905) | 20.2% | (6,304) | 21.1% | |
Increase/(decrease) in tax resulting from: | ||||
Tax credits | ||||
21 | (0.1%) | (340) | 1.1% | |
Unrecognized tax losses | ||||
4,385 | (22.7%) | 3,796 | (12.7%) | |
Non-deductible expenditure | ||||
52 | (0.3%) | 2,586 | (8.7%) | |
Temporary differences | ||||
328 | (1.7%) | 165 | (0.6%) | |
Other – net | ||||
34 | (0.1%) | 76 | (0.1%) | |
Total income tax expense (income) | ||||
915 | (4.7%) | (21) | 0.1% |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Current income tax expense | ||
US$’000 | US$’000 | |
Swiss corporate income taxes | ||
(27) | 58 | |
United States state and federal taxes | ||
455 | 393 | |
Taiwan corporate income taxes | ||
229 | 118 | |
Belgium corporate income taxes | ||
37 | (123) | |
Germany corporate income taxes | ||
(24) | 51 | |
United Kingdom corporate income taxes | ||
89 | - | |
Others | ||
1 | 63 | |
Total current income tax expense | ||
760 | 560 | |
Switzerland | ||
518 | 90 | |
United States | ||
(38) | (606) | |
China | ||
6 | 117 | |
Austria | ||
3 | 20 | |
Belgium | ||
(198) | (136) | |
Germany | ||
(91) | (68) | |
Others | ||
(45) | 2 | |
Total deferred income tax expense (income) | ||
155 | (581) | |
Total income tax expense (income) | ||
915 | (21) |
Switzerland | ||
518 | 90 | |
United States | ||
(38) | (606) | |
China | ||
6 | 117 | |
Austria | ||
3 | 20 | |
Belgium | ||
(198) | (136) | |
Germany | ||
(91) | (68) | |
Others | ||
(45) | 2 | |
Total deferred income tax expense (income) | ||
155 | (581) | |
Total income tax expense (income) | ||
915 | (21) |
Period ended | Year ended | |
June 30, | ||
December 31, | ||
2024 | ||
2022 | ||
Items that will not be reclassified subsequently to profit or loss | ||
US$’000 | US$’000 | |
Remeasurement of net defined benefit liability | ||
42 | (276) | |
Total income tax recognized in other comprehensive income | ||
42 | (276) |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Net tax(assets)/liabilities | ||
US$’000 | US$’000 | |
Opening balance – (prepaid taxes) | ||
(343) | 51 | |
Assumed on business combinations | ||
- | - | |
Assumed on asset acquisition | ||
- | (32) | |
Income tax expense for the year | ||
760 | 560 | |
Taxes paid | ||
(1,023) | (870) | |
Foreign currency differences | ||
- | (52) | |
Net tax (asset)/liability | ||
(606) | (343) |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Net tax(assets) liabilities | ||
US$’000 | US$’000 | |
Prepaid income taxes | ||
(795) | (657) | |
Income tax liabilities | ||
189 | 314 | |
Net tax (asset)/liability | ||
(606) | (343) |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Earnings | ||
US$’000 | US$’000 | |
Loss attributable to the ordinary equity holders of the parent entity | ||
(20,839) | (29,251) |
Period ended | Year ended | |
June 30, | December 31, | |
Number of shares | ||
2024 | 2022 | |
Weighted average number of ordinary shares for the purposes of basic | ||
earnings per share | ||
158,135,830 | ||
133,426,953 |
Goodwill | ||||||
Internally | ||||||
developed | ||||||
assets | ||||||
Brand names | ||||||
and customer | ||||||
relations | ||||||
Acquired | ||||||
technologies | ||||||
Other | ||||||
intangible | ||||||
assets | Total | |||||
Cost | ||||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
As at January 1, 2022 | ||||||
21,382 | 3,509 | 4,503 | 3,180 | 2,332 | 34,906 | |
Additions arising from internal | ||||||
development | ||||||
- | 2,165 | - | - | - | 2,165 | |
Other acquisitions | ||||||
- | - | - | - | 1,700 | 1,700 | |
Disposals / write-offs | ||||||
- | (85) | - | - | (812) | (897) | |
Currency translation differences | ||||||
(795) | 5 | (160) | (165) | 14 | (1,101) | |
As at December 31, 2022 | ||||||
20,587 | 5,594 | 4,343 | 3,015 | 3,234 | 36,773 | |
Business combinations | ||||||
764 | - | 150 | - | 507 | 1,421 | |
Additions arising from internal | ||||||
development | ||||||
- | 1,277 | - | - | - | 1,277 | |
Other acquisitions | ||||||
- | - | - | - | 150 | 150 | |
Disposals / write-offs | - | (1,169) | - | - | (1,806) | (2,975) |
Deconsolidation of subsidiary | ||||||
(123) | - | - | - | - | (123) | |
Currency translation differences | ||||||
70 | 141 | 14 | 7 | 106 | 338 | |
As at June 30, 2024 | ||||||
21,298 | 5,843 | 4,507 | 3,022 | 2,191 | 36,861 | |
Amortization and accumulated impairment losses | ||||||
As at January 1, 2022 | 2,305 | 474 | 602 | 234 | 518 | 4,133 |
Amortization for the year | ||||||
- | 198 | 695 | 334 | 208 | 1,435 | |
Impairment loss | ||||||
10,576 | 880 | 73 | - | 122 | 11,651 | |
Currency translation differences | ||||||
(750) | 3 | (72) | (45) | (24) | (888) | |
As at December 31, 2022 | ||||||
12,131 | 1,555 | 1,298 | 523 | 824 | 16,331 | |
Amortization for the year | ||||||
- | 1,136 | 1,057 | 500 | 545 | 3,238 | |
Disposals / write-offs | ||||||
- | (958) | - | - | (599) | (1,557) | |
Deconsolidation of subsidiary | (123) | - | - | - | - | (123) |
Impairment loss | ||||||
- | 323 | - | - | - | 323 | |
Currency translation differences | ||||||
19 | 30 | (46) | (30) | 5 | (22) | |
As at June 30, 2024 | ||||||
12,027 | 2,086 | 2,309 | 993 | 775 | 18,190 | |
Net book value | ||||||
As at December 31, 2022 | ||||||
8,456 | 4,039 | 3,045 | 2,492 | 2,410 | 20,442 | |
As at June 30, 2024 | ||||||
9,271 | 3,757 | 2,198 | 2,029 | 1,416 | 18,671 |
Balance | ||||
acquired | ||||
Accumulated | ||||
impairment | ||||
Currency | ||||
revaluation | Net book value | |||
Goodwill | ||||
US$’000 | US$’000 | US$’000 | US$’000 | |
ChemTex | ||||
3,393 | - | 3,393 | ||
Chrisal* | ||||
6,163 | (3,677) | (291) | 2,195 | |
RAS (incl. Tarn Pure in 2023/2024)* | ||||
7,998 | (4,007) | (308) | 3,683 | |
Life | ||||
5,202 | (5,202) | - | - | |
MasFabEs** | ||||
123 | (123) | - | - | |
Total goodwill | ||||
22,879 | (13,009) | (599) | 9,271 |
Assumption | ChemTex | Chrisal | RAS |
Discount factor | 9.3% | 9.8% | 8.3% |
Perpetual growth rate | 2.09% | 1.96% | 1.96% |
Compound annual growth rate for the next five years | 5.2% | 36.8% | 15.8% |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Goodwill book value | ||
US$’000 | US$’000 | |
ChemTex | ||
3,393 | 3,393 | |
Chrisal* | ||
2,195 | 2,189 | |
RAS (incl. Tarn Pure in 2023/2024)* | ||
3,683 | 2,874 | |
Life | ||
- | - | |
Total goodwill book value | ||
9,271 | ||
8,456 |
Machinery and | ||||||
equipment | Motor vehicles | |||||
Computers and | ||||||
software | ||||||
Furniture and | ||||||
fixtures | ||||||
Land and | ||||||
buildings | Total | |||||
Cost | ||||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
As at January 1, 2022 | ||||||
7,288 | 536 | 914 | 474 | 1,523 | 10,735 | |
Additions | ||||||
2,272 | 26 | 197 | 50 | 2,735 | 5,280 | |
Disposals | ||||||
(69) | (12) | - | - | - | (81) | |
Reclassifications | ||||||
(407) | 59 | - | 348 | - | - | |
Currency translation differences | ||||||
(233) | (1) | (21) | (23) | (90) | (368) | |
As at December 31, 2022 | ||||||
8,851 | 608 | 1,090 | 849 | 4,168 | 15,566 | |
Additions | ||||||
1,319 | 113 | 32 | 62 | 5,505 | 7,031 | |
Disposals | ||||||
(1,748) | (59) | (748) | (207) | - | (2,762) | |
Deconsolidation of subsidiary | ||||||
(1,265) | (30) | (11) | (33) | - | (1,339) | |
Reclassifications | ||||||
(37) | - | - | 37 | - | - | |
Currency translation differences | ||||||
76 | 1 | 27 | 10 | (68) | 46 | |
As at June 30, 2024 | ||||||
7,196 | 633 | 390 | 718 | 9,605 | 18,542 | |
Depreciation and accumulated impairment | ||||||
losses | ||||||
As at January 1, 2022 | ||||||
2,723 | 330 | 619 | 86 | 112 | 3,870 | |
Charge for the year | ||||||
763 | 90 | 218 | 83 | 128 | 1,282 | |
Eliminated on disposal | ||||||
(27) | (5) | - | - | - | (32) | |
Impairment loss | ||||||
730 | - | - | - | - | 730 | |
Reclassifications | ||||||
(222) | - | - | 222 | - | - | |
Currency translation differences | (67) | - | (9) | (3) | (7) | (86) |
As at December 31, 2022 | ||||||
3,900 | 415 | 828 | 388 | 233 | 5,764 | |
Charge for the year | ||||||
1,421 | 114 | 148 | 152 | 480 | 2,315 | |
Eliminated on disposal | ||||||
(736) | (35) | (743) | (198) | - | (1,712) | |
Deconsolidation of subsidiary | ||||||
(1,210) | (8) | (5) | (8) | - | (1,231) | |
Reclassifications | ||||||
7 | - | (6) | (1) | - | - | |
Currency translation differences | ||||||
67 | 1 | 22 | 7 | (3) | 94 | |
As at June 30, 2024 | ||||||
3,449 | 487 | 244 | 340 | 710 | 5,230 | |
Net book value | ||||||
As at December 31, 2022 | ||||||
4,951 | 193 | 262 | 461 | 3,935 | 9,802 | |
As at June 30, 2024 | ||||||
3,747 | 146 | 146 | 378 | 8,895 | 13,312 |
Land and buildings | Motor vehicles | |||
Machinery and | ||||
equipment | Total | |||
Cost | ||||
US$’000 | US$’000 | US$’000 | US$’000 | |
As at January 1, 2022 | ||||
8,913 | 611 | 341 | 9,865 | |
Additions | ||||
86 | 174 | 1,921 | 2,181 | |
Disposals due to expiry of lease | ||||
- | (36) | - | (36) | |
Disposals due to business combination* | ||||
(467) | - | - | (467) | |
Modification to lease terms** | ||||
(1,199) | - | - | (1,199) | |
Currency translation differences | ||||
(381) | (67) | (26) | (474) | |
As at December 31, 2022 | ||||
6,952 | 682 | 2,236 | 9,870 | |
Additions | ||||
860 | 140 | 913 | 1,913 | |
Disposals due to expiry of lease | ||||
(475) | (40) | (32) | (547) | |
Modification to lease terms*** | ||||
(1,228) | (110) | - | (1,338) | |
Currency translation differences | ||||
(58) | 19 | (29) | (68) | |
As at June 30, 2024 | ||||
6,051 | 691 | 3,088 | 9,830 | |
Depreciation | ||||
As at January 1, 2022 | ||||
1,716 | 109 | 66 | 1,891 | |
Depreciation for the year | ||||
730 | 140 | 68 | 938 | |
Disposals due to expiry of lease | ||||
- | (36) | - | (36) | |
Modification to lease terms** | ||||
(693) | - | - | (693) | |
Currency translation differences | ||||
(34) | (6) | (9) | (49) | |
As at December 31, 2022 | ||||
1,719 | 207 | 125 | 2,051 | |
Depreciation for the year | ||||
1,096 | 232 | 245 | 1,573 | |
Disposals due to expiry of lease | ||||
(301) | (25) | (33) | (359) | |
Modification to lease terms*** | ||||
(990) | (41) | - | (1,031) | |
Currency translation differences | ||||
(134) | (1) | (1) | (136) | |
As at June 30, 2024 | ||||
1,390 | 372 | 336 | 2,098 | |
Net book value | ||||
As at December 31, 2022 | ||||
5,233 | 475 | 2,111 | 7,819 | |
As at June 30, 2024 | ||||
4,661 | 319 | 2,752 | 7,732 |
Period ended | ||
June 30, | ||
2024 | ||
Year ended | ||
December 31, | ||
2022 | ||
US$’000 | US$’000 | |
Depreciation expense on right-of-use assets | ||
1,573 | 938 | |
Interest expense on lease liabilities | ||
311 | 163 | |
Expense relating to short-term leases | ||
374 | 225 | |
Expense relating to leases of low value assets | ||
51 | 40 | |
Gain from early disposal and modification of leases | ||
33 | 68 |
Period ended | ||
June 30, | ||
2024 | ||
Year ended | ||
December 31, | ||
2022 | ||
US$’000 | US$’000 | |
Total fixed lease payments | ||
1996 | 992 | |
Gain from early disposal and modification of leases | ||
(33) | (68) | |
Interest paid on leases | ||
311 | 163 |
As at | ||
As at | ||
June 30, | December 31 | |
2024 | 2022 | |
Other non-current assets | ||
US$’000 | US$’000 | |
Deposits | ||
72 | ||
80 | ||
Other prepayments | ||
7 | ||
57 | ||
Other non-current assets | ||
79 | ||
137 |
As at | ||
As at | ||
June 30, | December 31 | |
2024 | 2022 | |
Inventories | ||
US$’000 | US$’000 | |
Gross inventories | ||
12,616 | 18,564 | |
Allowance for inventories | ||
(4,360) | (5,396) | |
Net realizable value | ||
8,256 | 13,168 |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Trade receivables | ||
US$’000 | US$’000 | |
Not past due | ||
2,791 | 2,788 | |
<30 days | ||
2,011 | 520 | |
31-60 days | ||
671 | 781 | |
61-90 days | ||
234 | 215 | |
91-120 days | ||
46 | 180 | |
>120 days | ||
1,782 | 2,407 | |
Total trade receivables | ||
7,535 | 6,891 | |
Provision for expected credit losses | ||
(1,280) | (404) | |
Total trade receivables (net) | ||
6,255 | 6,487 |
Trade receivables – days past due | |||||
Not past due | 1-60 | 61-120 | >120 days | Total | |
Expected credit loss | |||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Expected credit loss rate | |||||
1% | 1% | 1% | 68% | 17% | |
Estimated total gross carrying amount at default | |||||
2,791 | 2,682 | 280 | 1,782 | 7,535 | |
Lifetime ECL as at June 30, 2024 | |||||
40 | 18 | 2 | 1,220 | 1,280 |
Trade receivables – days past due | |||||
Not past due | 1-60 | 61-120 | >120 days | Total | |
Expected credit loss | |||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Expected credit loss rate | |||||
0% | 0% | 0% | 17% | 6% | |
Estimated total gross carrying amount at default | |||||
2,788 | 1,301 | 395 | 2,407 | 6,891 | |
Lifetime ECL as at December 31, 2022 | |||||
- | - | - | 404 | 404 |
Individually | |||
assessed | |||
Collectively | |||
assessed | Total | ||
Expected credit losses | |||
US$’000 | US$’000 | US$’000 | |
Balance as at January 1, 2022 | |||
278 | 46 | 324 | |
Net remeasurement of loss allowance | |||
172 | (6) | 166 | |
Amounts written off | |||
(81) | - | (81) | |
Foreign exchange gains and losses | |||
(4) | (1) | (5) | |
Balance as at December 31, 2022 | |||
365 | 39 | 404 | |
Net remeasurement of loss allowance | |||
878 | 85 | 963 | |
Amounts written off | |||
(97) | - | (97) | |
Foreign exchange gains and losses | |||
12 | (2) | 10 | |
Balance as at June 30, 2024 | |||
1,158 | 122 | 1,280 |
Period ended | ||
June 30, | ||
2024 | ||
US$’000 | ||
Year ended | ||
December 31, | ||
2022 | ||
US$’000 | ||
Origination of new trade receivables net of those settled, as well as increase in days past | ||
due up to 120 days | ||
878 | 172 | |
Write-off of receivables older than 120 days | ||
(97) | (81) |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Other receivables and prepayments | ||
US$’000 | US$’000 | |
Contract assets | ||
83 | 115 | |
Receivables from tax authorities | ||
1,804 | 1,864 | |
Prepayments | ||
769 | 1,023 | |
Other receivables | ||
269 | 1,260 | |
Total other receivables and prepayments | ||
2,925 | 4,262 |
As at | |||
June 30, | |||
As at | |||
December 31, | |||
As at | |||
January 1, | |||
2024 | 2022 | 2022 | |
Contract assets | |||
US$’000 | US$’000 | US$’000 | |
Research and development services | |||
83 | 65 | 80 | |
Take-or-pay services | |||
- | - | 170 | |
Exclusivity services | |||
- | 50 | - | |
Total contract assets | |||
83 | 115 | 250 | |
Current assets | |||
83 | |||
115 | 250 | ||
Non-current assets | |||
- | |||
- | - | ||
Total contract assets | |||
- | |||
115 | 250 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
Expected credit loss | ||
US$’000 | US$’000 | |
Expected credit loss rate | ||
0% | 0% | |
Estimated total gross carrying amount at default | ||
83 | 115 | |
Lifetime ECL | ||
- | - | |
Net carrying amount | ||
83 | 115 |
Note | Number of shares | Share capital | Share premium | Totals | |
No. | US$’000 | US$’000 | US$’000 | ||
Balance as of January 1, 2022 | |||||
130,583,536 | 51,523 | 144,191 | 195,714 | ||
Issue of shares to vendors of Life Materials | |||||
347,552 | 141 | 471 | 612 | ||
Issue of shares as deferred consideration | |||||
3,461,615 | 1,359 | 2,921 | 4,280 | ||
Issue of shares to Advisory Board and others | |||||
164,721 | 60 | 175 | 235 | ||
Issue of shares ChemTex Labs | |||||
2,176,884 | 795 | 1,177 | 1,972 | ||
Issue of shares Chrisal | |||||
3,348,164 | 1,223 | 1,838 | 3,061 | ||
Balance as at December 31, 2022 | |||||
140,082,472 | 55,101 | 150,773 | 205,874 | ||
Issue of shares Tarn Pure (a) | |||||
455,435 | 160 | 212 | 372 | ||
Issue of shares from fundraise (b) | |||||
28,000,000 | 1,752 | 1,296 | 3,048 | ||
Balance as at June 30, 2024 | |||||
168,537,907 | 57,013 | 152,281 | 209,294 |
Period ended June 30, 2024 | ||||
Year ended December 31, 2022 | ||||
Number of | ||||
options | ||||
Weighted average | ||||
exercise price (£) | ||||
Number of | ||||
options | ||||
Weighted average | ||||
exercise price (£) | ||||
Outstanding at beginning of period/year | ||||
11,525,911 | 1.05 | |||
8,707,65 | 8 1.14 | |||
Granted during the period/year | ||||
10,300,000 | 0.09 | |||
3,349,12 | 5 0.83 | |||
Forfeited during the period/year | ||||
(2,364,362) | 1.06 | |||
(530,872) | 1.12 | |||
Lapsed during the period/year | ||||
(3,783,496) | 1.23 | |||
Vested during the period/year | ||||
(1,046,504) | 1.23 | |||
- | - | |||
Exercised during the period/year | ||||
- | - | |||
- | - | |||
Expired during the period/year | ||||
- | - | - | - | |
Outstanding at the end of the period | ||||
14,631,549 | 0.31 | |||
11,525,911 | 1.05 | |||
Exercisable at the end of the period | 1,046,504 | |||
1.23 | ||||
- | ||||
- |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Model used | ||
Monte Carlo | Black Scholes | |
Weighted average share price (£) | ||
0.0860 | 0.817 | |
Weighted average exercise price (£) | ||
0.0898 | 0.834 | |
Expected volatility | ||
65.0% | 69.3%/70.3%* | |
Expected life | ||
2.7 years | ||
2.6 /2.3 | ||
Risk-free rate | ||
4.32% | 1.90%/4.38%* | |
Expected dividend yields | ||
0% | 0% | |
Share price hurdle | ||
£0.3250 | n/a |
Share- based | ||||||
payment | ||||||
reserve | ||||||
Merger | ||||||
reserve | ||||||
Currency | ||||||
translation | ||||||
reserve | Other reserve | |||||
Total Other | ||||||
reserves | ||||||
Note | ||||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | ||
Balance at January 1, 2022 | ||||||
474 | (126,912) | 387 | (1,144) | (127,195) | ||
Other comprehensive (loss)/income | ||||||
- | - | (1,914) | 1,104 | (810) | ||
Total comprehensive (loss)/income for | ||||||
the year | ||||||
- | - | (1,914) | 1,104 | (810) | ||
Share-based payment charges | ||||||
2 | ||||||
7 | ||||||
(12) | - | - | - | (12) | ||
Transactions with owners | ||||||
(12) | - | - | - | (12) | ||
Balance at December 31, 2022 | ||||||
462 | (126,912) | (1,527) | (40) | (128,017) | ||
Other comprehensive (loss)/income | ||||||
- | - | 466 | (136) | 330 | ||
Total comprehensive (loss)/income for | ||||||
the year | ||||||
- | - | 466 | (136) | 330 | ||
Share-based payment | ||||||
charges/(reversal) | ||||||
2 | ||||||
7 | ||||||
(51) | - | - | - | (51) | ||
Transactions with owners | ||||||
(51) | - | - | - | (51) | ||
Balance at June 30, 2024 | ||||||
411 | (126,912) | (1,061) | (176) | (127,738) |
As at | ||
As at | ||
June 30, | December 31, | |
Net benefit obligations | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Fair value of plan assets | ||
7,245 | ||
9,616 | ||
Defined benefit obligations | ||
(8,094) | (10,568) | |
Funded status (net liability) | ||
(849) | (952) | |
Duration (years) | ||
15.8 | ||
13.8 | ||
Expected benefits payable in following year | ||
(351) | ||
(389) |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Development of obligations and assets | ||
US$’000 | US$’000 | |
Present value of funded obligations, beginning of period/year | ||
(10,568) | (13,003) | |
Employer service cost | ||
(571) | (571) | |
Employee contributions | ||
(452) | (352) | |
Past service cost | ||
341 | - | |
Curtailments/Settlements | ||
148 | - | |
Interest cost | ||
(302) | (45) | |
Benefits paid/(refunded) | ||
4,309 | 522 | |
Actuarial (loss)/gain on benefit obligation | ||
(636) | 2,562 | |
Currency (loss)/gain | ||
(363) | 319 | |
Present value of funded obligations, end of period/year | ||
(8,094) | (10,568) | |
Defined benefit obligation participants | ||
(6,746) | (10,568) | |
Defined benefit obligation pensioners | ||
(1,348) | - | |
Present value of funded obligations, end of period/year | ||
(8,094) | (10,568) | |
Fair value of plan assets, beginning of period/year | ||
9,616 | 10,858 | |
Expected return on plan assets | ||
273 | 37 | |
Employer’s contributions | ||
448 | 352 | |
Employees’ contributions | ||
452 | 352 | |
Benefits (paid)/refunded | ||
(4,309) | (522) | |
Admin expense | ||
(28) | (21) | |
Actuarial (loss)/gain on plan assets | ||
458 | (1,182) | |
Currency gain/(loss) | ||
335 | (258) | |
Fair value of plan assets, end of period/year | ||
7,245 | 9,616 |
Period ended | Year ended | |
June 30, | December 31, | |
Movements in net liability recognized in statement of financial position: | ||
2024 | ||
US$’000 | ||
2022 | ||
US$’000 | ||
Net liability, beginning of year | ||
(952) | (2,146) | |
Employer service cost | ||
(571) | (571) | |
Interest cost | ||
(302) | (45) | |
Expected return on plan assets | ||
273 | 37 | |
Admin expense | ||
(28) | (21) | |
Past service cost recognized in period/year | ||
341 | - | |
Curtailment, settlement, plan amendment gain (loss) | ||
148 | - | |
Employer’s contributions (following year expected contributions) | ||
448 | 352 | |
Prepaid (accrued) pension cost: | ||
(311) | 247 | |
- operating income (expense) | ||
339 | (240) | |
- finance expense | ||
(28) | (7) |
Total gains recognized within other comprehensive income | ||
(178) | 1,380 | |
Currency loss | ||
(28) | 62 | |
Net liability, end of period/year | ||
(849) | (952) | |
Expected employer's cash contributions for following period/year | ||
264 | 360 |
Period ended | Year ended | |
June 30, | December 31, | |
Amounts recognized in profit and loss | ||
2024 | ||
US$’000 | ||
2022 | ||
US$’000 | ||
Employer service cost | ||
(571) | (571) | |
Past service cost recognized in period/year | ||
341 | - | |
Interest cost | ||
(302) | (45) | |
Expected return on plan assets | ||
273 | 37 | |
Admin expense | ||
(28) | (21) | |
Curtailment, settlement, plan amendment gain (loss) | ||
150 | - | |
Components of defined benefit costs recognized in profit or loss | ||
(137) | (600) |
Period ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Amounts recognized in other comprehensive income | ||
US$’000 | US$’000 | |
Actuarial gains/(losses) arising from plan experience | ||
212 | 193 | |
Actuarial (losses)/gains arising from demographic assumptions | ||
- | (23) | |
Actuarial gains arising from financial assumptions | ||
(848) | 2,392 | |
Re-measurement of defined benefit obligations | ||
(636) | 2,562 | |
Re-measurement of assets | ||
458 | (1,182) | |
Deferred tax asset derecognized / (recognized) | ||
42 | (276) | |
Total recognized in OCI | ||
(136) | 1,104 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
Asset allocation | ||
2024 | 2022 | |
Cash | ||
1.2% | 2.8% | |
Bonds | ||
30.2% | 29.1% | |
Equities | ||
34.4% | 33.2% | |
Property (incl. mortgages) | ||
28.8% | 31.3% | |
Other | ||
5.4% | 3.6% | |
Total | ||
100.0% | 100.0% |
As at | ||
As at | ||
June 30, | December 31, | |
The principal assumptions | ||
2024 | 2022 | |
Discount rate | ||
1.50% | 2.25% | |
Interest credit rate | ||
2.00% | 2.25% | |
Average future salary increases | ||
1.50% | 2.50% | |
Future pension increases | ||
0.00% | 0.00% | |
Mortality tables used | ||
BVG 2020 GT | ||
BVG 2020 GT | ||
Average retirement age | ||
65/65 | ||
65/65 |
As at | ||
As at | ||
June 30, | December 31, | |
Impact on defined benefit obligation | ||
2024 | 2022 | |
Discount rate + 0.25% | ||
(308) | (323) | |
Discount rate – 0.25% | ||
329 | 343 | |
Salary increase + 0.25% | ||
44 | 44 | |
Salary increase – 0.25% | ||
(43) | (43) | |
Pension increase + 0.25% | ||
165 | 167 | |
Pension decrease – 0.25% (not lower than 0%) | ||
- | - |
As at | ||
June 30, | ||
2024 | ||
As at | ||
December 31, | ||
2022 | ||
Lease liabilities | ||
US$’000 | US$’000 | |
Not later than one year | ||
1,151 | 1,301 | |
Later than one year and not later than five years | ||
3,398 | 3,813 | |
Later than five years | ||
3,271 | 3,387 | |
Total minimum lease payments | ||
7,820 | 8,501 | |
Less: Future finance charges | ||
(539) | (679) | |
Present value of minimum lease payments | ||
7,281 | 7,822 | |
Current liability | ||
997 | 1,264 | |
Non-current liability | ||
6,284 | 6,558 | |
7,281 | 7,822 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
Borrowings | ||
US$’000 | US$’000 | |
Unsecured bank loans | ||
9,973 | 3,573 | |
Secured bank loans | ||
793 | 628 | |
Loans from related parties | ||
443 | - | |
Loans from non-controlling interest | ||
- | 137 | |
Total borrowings | ||
11,209 | 4,338 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Not later than one year | ||
9,380 | 2,893 | |
Later than one year but less than five years | ||
884 | 1,029 | |
After more than five years | ||
945 | 416 | |
Total borrowings | ||
11,209 | 4,338 |
As at June 30, 2024 | As at December 31, 2022 | ||||||
Description | Currency | Repayment date | |||||
Principal | |||||||
US$’000 | |||||||
Interest rate | |||||||
Principal | |||||||
US$’000 | |||||||
Interest rate | |||||||
Credit facility | |||||||
CHF | August 2024 | ||||||
550 | 7.10% | - | - | ||||
Credit facility | |||||||
CHF | September 2024 | ||||||
1,100 | 5.45% | - | - | ||||
Credit facility | |||||||
CHF | July 2024 | ||||||
5,829 | 4.44% | 2,574 | 2.20% | ||||
Credit facility | |||||||
CHF | July 2024 | ||||||
550 | 4.40% | - | - | ||||
Credit facility | |||||||
EUR | July 2024 | ||||||
415 | 6.82% | - | - | ||||
Various bank loans | |||||||
1) | |||||||
EUR | 1-10 years | ||||||
1,504 | 3,04% | 999 | 2.21% | ||||
Bank loan | |||||||
GBP | May 2026 | ||||||
25 | 2.50% | - | - | ||||
Outstanding at the end of the year | |||||||
9,973 | 3,573 |
Pension fund | |||||
obligations | |||||
Tax losses | Share-based | ||||
payments | |||||
Temporary | |||||
differences | |||||
Total | |||||
Deferred tax | |||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Balance at January 1, 2022 | 429 | 178 | 85 | (1,686) | (994) |
Charge/(credit) | |||||
to profit or loss | |||||
49 | (150) | 1 | 681 | 581 | |
Credit | |||||
to other comprehensive income | |||||
(276) | - | - | - | (276) | |
Foreign currency differences | |||||
(12) | (28) | 5 | 9 | (26) | |
Balance as at December 31, 2022 | |||||
190 | - | 91 | (996) | (715) | |
Charge/(credit) | |||||
to profit or loss | |||||
(457) | - | (87) | 389 | (155) | |
Charge to other comprehensive income | |||||
42 | - | - | - | 42 | |
Arising from business combinations | |||||
- | - | - | (164) | (164) | |
Foreign currency differences | |||||
20 | - | (4) | 8 | 24 | |
Balance as at June 30, 2024 | |||||
(205) | - | - | (763) | (968) |
Year ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
US$’000 | US$’000 | |
Deferred tax | ||
Deferred tax assets | ||
305 | 538 | |
Deferred tax liabilities | ||
(1,273) | (1,253) | |
Net deferred tax assets (liabilities) | ||
(968) | (715) |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Defined benefit obligation IAS 19 Switzerland (Note 29) | ||
849 | 952 | |
Defined benefit obligation IAS 19 Thailand (Note 29) | ||
134 | 134 | |
Contract liabilities | ||
4,758 | 3,614 | |
Deferred grant income | ||
- | 14 | |
Total other non-current liabilities | ||
5,741 | 4,714 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Trade payables | ||
3,706 | 3,321 | |
Payables to tax authorities | ||
315 | 375 | |
Other payables | ||
1,940 | 1,626 | |
Total trade and other payables | ||
5,961 | 5,322 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Costs of goods sold | ||
837 | 875 | |
Personnel expenses | 1,202 | 1,737 |
Other operating expenses | ||
1,027 | 2,366 | |
Total accrued liabilities | ||
3,066 | 4,978 |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Contract liabilities | ||
1,700 | 1,176 | |
Prepayments for unshipped goods | ||
120 | 94 | |
Deferred grant income | ||
92 | 15 | |
Total deferred revenue | ||
1,912 | 1,285 |
As at | |||
June 30, | |||
As at | |||
December 31, | |||
As at | |||
January 1, | |||
2024 | 2022 | 2022 | |
US$’000 | US$’000 | US$’000 | |
Exclusivity agreements | |||
2,107 | 1,832 | - | |
Research and development services | |||
4,351 | 2,958 | 1,000 | |
Total contract liabilities | |||
6,458 | 4,790 | 1,000 | |
Current liabilities (Note 36) | |||
1,700 | 1,176 | 1,000 | |
Non-current liabilities (Note 33) | |||
4,758 | 3,614 | - | |
Total contract liabilities | |||
6,458 | 4,790 | 1,000 |
Period ended | ||
June 30, | ||
Year ended | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Exclusivity agreements | ||
785 | ||
- | ||
Research and development services | ||
905 | ||
- | ||
Total revenue recognized from contract liabilities | ||
1,690 | ||
- |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Deferred consideration in relation to acquisitions | ||
169 | 92 | |
Call option derivative liability | ||
333 | 686 | |
Other current liabilities | ||
502 | 778 |
ChemTex | RAS AG | Life | Tarn Pure | Total | |
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
As at January 1, 2022 | |||||
279 | 3,152 | 2,652 | - | 6,083 | |
Foreign exchange revaluation | |||||
- | (277) | - | - | (277) | |
Consideration settled in cash | |||||
(187) | - | (1,400) | - | (1,587) | |
Consideration settled in shares | |||||
- | (2,875) | (1,252) | - | (4,127) | |
As at December 31, 2022 | |||||
92 | - | - | - | 92 | |
Additions from acquisition as per Note 5a | |||||
- | - | - | 244 | 244 | |
Consideration settled in cash | |||||
- | - | - | (180) | (180) | |
Amortization of fair value discount | |||||
- | - | - | 3 | 3 | |
Foreign exchange revaluation | |||||
- | - | - | 10 | 10 | |
As at June 30, 2024 | |||||
92 | - | - | 77 | 169 |
Weighted average share price (€) | |
2,285.71 | |
Weighted average exercise price (€) | |
2,500.00 | |
Expected volatility | |
22.5% | |
Expected life | |
0.5 year | |
Risk-free rate | |
1.0% | |
Expected dividend yield | |
0% |
As at | ||
June 30, | ||
As at | ||
December 31, | ||
Provisions | ||
2024 | 2022 | |
US$’000 | US$’000 | |
Legal/Compliance provision | ||
- | 339 | |
Total provisions | ||
- | 339 |
Current liability | ||
- | 339 | |
Non-current liability | ||
- | - | |
Total provisions | ||
- | 339 |
Legal/Compliance | ||
provision | Total | |
US$’000 | US$’000 | |
Provisions | ||
Balance at January 1, 2022 | ||
- | - | |
Additional provision in the year | ||
339 | 339 | |
Utilization of provision | ||
- | - | |
Exchange difference | ||
- | - | |
Balance as at December 31, 2022 | ||
339 | 339 | |
Additional provision in the year | ||
- | - | |
Utilization of provision | ||
(339) | (339) | |
Exchange difference | ||
- | - | |
Balance as at June 30, 2024 | ||
- | - |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Financial instruments | ||
US$’000 | US$’000 | |
Cash and cash equivalents | ||
5,027 | 8,488 | |
Trade receivables | ||
6,255 | 6,487 | |
Accrued income and other receivables | ||
2,156 | 3,239 | |
Trade and other payables | ||
(5,961) | (5,322) | |
Accrued liabilities | ||
(3,066) | (4,978) | |
Deferred consideration | ||
(169) | (92) | |
Call option derivative liability | ||
(333) | (686) | |
Borrowings held at amortized cost | ||
(11,209) | (4,338) | |
Lease liabilities held at present value of lease payments | ||
(7,281) | (7,823) | |
Total financial instruments | ||
(14,581) | (5,025) |
Functional currency | ||||||
AUD | EUR | GBP | US$ | Others | Total | |
As at June 30, 2024 | ||||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Financial assets denominated in $ | ||||||
- | 153 | 3 | 1,386 | (4) | 1,538 | |
Financial liabilities denominated in $ | ||||||
- | (163) | - | 407 | - | 244 | |
Net foreign currency exposure | ||||||
- | (10) | 3 | 1,793 | (4) | 1,782 |
Functional currency | ||||||
AUD | EUR | GBP | US$ | Others | Total | |
As at December 31, 2022 | ||||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Financial assets denominated in $ | ||||||
19 | 92 | 206 | 6,771 | 3 | 7,091 | |
Financial liabilities denominated in $ | ||||||
- | - | - | - | - | - | |
Net foreign currency exposure | ||||||
19 | 92 | 206 | 6,771 | 3 | 7,091 |
AUD | EUR | GBP | US$ | Others | |
As at June 30, 2024 | |||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Effect on net assets: | |||||
Strengthened by 10% | |||||
- | (1) | - | 179 | 178 | |
Weakened by 10% | |||||
- | 1- | - | (179) | (178) |
AUD | EUR | GBP | US$ | Others | |
As at December 31, 2022 | |||||
US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
Effect on net assets: | |||||
Strengthened by 10% | |||||
2 | 9 | 21 | 677 | - | |
Weakened by 10% | |||||
(2) | (9) | (21) | (677) | - |
Less than | ||||
1 year | ||||
2 to 5 | ||||
years | ||||
> 5 | ||||
years | Total | |||
As at June 30, 2024 | ||||
US$’000 | US$’000 | US$’000 | US$’000 | |
Trade and other payables | ||||
5,961 | - | - | 5,961 | |
Borrowings held at amortized cost | ||||
9,380 | 884 | 945 | 11,209 | |
Leases (gross cash flows) | ||||
1,151 | 3,398 | 3,271 | 7,820 | |
Other liabilities | ||||
3,255 | - | - | 3,255 | |
Financing facilities | ||||
19,747 | 4,282 | 4,216 | 28,245 |
Less than | ||||
1 year | ||||
2 to 5 | ||||
years | ||||
> 5 | ||||
years | Total | |||
As at December 31, 2022 | ||||
US$’000 | US$’000 | US$’000 | US$’000 | |
Trade and other payables | ||||
5,322 | - | - | 5,322 | |
Borrowings held at amortized cost | ||||
2,893 | 1,029 | 416 | 4,338 | |
Leases (gross cash flows) | ||||
1,302 | 3,813 | 3,387 | 8,502 | |
Other liabilities | ||||
5,290 | - | - | 5,290 | |
Financing facilities | ||||
14,807 | 4,842 | 3,803 | 23,452 |
As at | ||
June 30, | ||
2024 | ||
As at | ||
December 31, | ||
2022 | ||
Unsecured bank overdraft facility | ||
US$’000 | US$’000 | |
Amount used | ||
8,935 | 2,790 | |
Amount unused | ||
414 | 6,861 | |
Total | ||
9,349 | 9,651 |
As at | ||
As at | ||
June 30, | December 31, | |
2024 | 2022 | |
Equity ratio | ||
US$’000 | US$’000 | |
Equity | ||
25,428 | 40,339 | |
Total equity and liabilities | ||
62,562 | 71,143 | |
Equity ratio | ||
41% | 57% |
Note | |||
As at | |||
June 30, | |||
As at | |||
December 31, | |||
2024 | 2022 | ||
Gains and losses on disposal of assets | |||
US$’000 | US$’000 | ||
Gain on disposal of property, plant and equipment | |||
10 | |||
(23) | (21) | ||
Loss on disposal of property, plant and equipment | |||
13 | |||
204 | 16 | ||
Net loss (gain) on disposal of assets | |||
181 | (5) |
Liabilities arising from financing activities | |||
Leases | |||
US$’000 | |||
Borrowings | |||
US$’000 | |||
Total | |||
US$’000 | |||
Balance at January 1, 2022 | |||
8,114 | 2,762 | 10,876 | |
Cash flows | |||
(992) | 2,561 | 1,569 | |
New lease agreements | |||
2,181 | - | 2,181 | |
Revaluation of lease agreements | |||
(574) | - | (574) | |
Disposal due to acquisitions | |||
(490) | - | (490) | |
Loans waived by creditors | |||
- | (764) | (764) | |
Exchange differences | |||
(416) | (221) | (637) | |
Balance at December 31, 2022 | |||
7,823 | 4,338 | 12,161 | |
Cash flows | |||
(1,996) | 7,300 | 5,304 | |
New lease agreements | |||
1,601 | - | 1,601 | |
Revaluation of lease agreements | |||
(213) | - | (213) | |
Derecognized following deconsolidation of subsidiary | |||
- | (304) | (304) | |
Exchange differences | |||
66 | (125) | (59) | |
Balance at June 30, 2024 | |||
7,281 | 11,209 | 18,490 |
Period ended June 30, 2024 | |||||
Opening balances | |||||
Assumed on | |||||
acquisition of | |||||
assets | |||||
Deconsolidation of | |||||
subsidiary | |||||
Change in | |||||
balance | |||||
Closing balances | |||||
US$’000 | US$’000 | US$’000 | US$’000 | ||
US$’000 | |||||
Inventories | |||||
13,168 | 13 | (5) | (4,920) | ||
8,256 | |||||
Trade receivables | |||||
6,487 | 2 | (18) | (216) | ||
6,255 | |||||
Other receivables and prepayments | |||||
4,262 | 10 | 900 | (2,247) | ||
2,925 | |||||
Trade and other receivables and prepayments | |||||
10,749 | 12 | 882 | (2,463) | ||
9,180 | |||||
Trade and other payables | |||||
5,322 | 2 | (315) | 952 | ||
5,961 | |||||
Accrued liabilities | |||||
4,978 | - | - | (1,912) | ||
3,066 | |||||
Deferred revenue incl. non-current contract | |||||
liabilities | |||||
4,913 | - | (460) | 2,217 | ||
6,670 | |||||
Trade and other payables, accrued liabilities and | |||||
deferred revenue | |||||
15,213 | 2 | (775) | 1,257 | ||
15,697 |
Year ended December 31, 2022 | ||||
Opening balances | ||||
Assumed on | ||||
acquisition of | ||||
assets | ||||
Change in | ||||
balance | ||||
Closing balances | ||||
US$’000 | US$’000 | US$’000 | ||
US$’000 | ||||
Inventories | ||||
13,770 | - | (602) | ||
13,168 | ||||
Trade receivables | ||||
14,656 | - | (8,169) | 6,487 | |
Other receivables and prepayments | ||||
3,876 | - | 386 | 4,262 | |
Trade and other receivables and prepayments | 18,532 | - | (7,783) | 10,749 |
Trade and other payables | ||||
8,271 | - | (2,949) | 5,322 | |
Accrued liabilities | ||||
3,386 | 9 | 1,583 | 4,978 | |
Deferred revenue incl. non-current contract liabilities | ||||
1,004 | - | 3,909 | 4,913 | |
Trade and other payables, accrued liabilities and deferred revenue | 12,661 | 9 | 2,543 | 15,213 |
Period ended June 30, 2024 | |
US$’000 | |
Consideration payment for acquisition of Tarn Pure | |
801 | |
Cash assumed on acquisition of Tarn Pure | |
(12) | |
Net consideration payment for acquisitions of businesses and assets | |
789 |
Year ended December 31, 2022 | |
US$’000 | |
Consideration payment for acquisition of Life Materials Technologies Ltd | |
1,400 | |
Consideration payment for acquisition of ChemTex assets | |
187 | |
Net consideration payment for acquisitions of businesses and assets | |
1,587 |
As at | ||
June 30, | ||
2024 | ||
As at | ||
December 31, | ||
2022 | ||
Loans due to related parties | ||
US$’000 | US$’000 | |
Cortegrande AG, €400,000 (Note 31) | ||
443 | - | |
Loans due to related parties | ||
443 | - |
Year ended | Year ended | |
June 30, | December 31, | |
2024 | 2022 | |
Remuneration of key management personnel | ||
US$’000 | US$’000 | |
Short- | ||
term employee benefits | ||
1,042 | 738 | |
Post-employment benefits | ||
42 | 35 | |
Cash remuneration of key management personnel | ||
1,084 | 773 | |
Share-based payment expense (income) | 46 | (58) |
Total remuneration of key management personnel | ||
1,130 | 715 |